TCM
GNOM icon

Triumph Capital Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Triumph Capital Management’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.5K Hold
400
– – ﹤0.01% 938
2025
Q4 		$18.2K Buy
+400
New +$17.7K ﹤0.01% 893

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
AA
Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Triumph Capital Management's GNOM Position: Q1 2026 in Review

Triumph Capital Management held its Global X Genomics & Biotechnology ETF (GNOM) position steady in Q1 2026 at 400 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Triumph Capital Management first reported a position in GNOM in Q4 2025 and has held it in 2 quarters since. The position peaked at $18.2K in Q4 2025. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

  • Triumph Capital Management held 400 shares of Global X Genomics & Biotechnology ETF worth $17.5K as of Q1 2026.
  • Triumph Capital Management left its Global X Genomics & Biotechnology ETF share count unchanged in Q1 2026.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of Triumph Capital Management's portfolio in Q1 2026, its #938 holding.
  • Triumph Capital Management first reported a position in Global X Genomics & Biotechnology ETF in Q4 2025 and has held it in 2 quarters since.
  • Triumph Capital Management's Global X Genomics & Biotechnology ETF position peaked at $18.2K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on Triumph Capital Management's 13F filing for Q1 2026, filed 13 May 2026.